IL242759A - - Google Patents

Info

Publication number
IL242759A
IL242759A IL24275915A IL24275915A IL242759A IL 242759 A IL242759 A IL 242759A IL 24275915 A IL24275915 A IL 24275915A IL 24275915 A IL24275915 A IL 24275915A IL 242759 A IL242759 A IL 242759A
Authority
IL
Israel
Application number
IL24275915A
Other languages
Hebrew (he)
Other versions
IL242759B1 (en
IL242759B2 (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51063834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL242759(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of IL242759A publication Critical patent/IL242759A/he
Publication of IL242759B1 publication Critical patent/IL242759B1/en
Publication of IL242759B2 publication Critical patent/IL242759B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4883—Capsule finishing, e.g. dyeing, aromatising, polishing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL242759A 2013-06-06 2015-11-24 Pharmaceutical formulations of hif hydroxylase inhibitor IL242759B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361831909P 2013-06-06 2013-06-06
PCT/US2014/041021 WO2014197660A1 (en) 2013-06-06 2014-06-05 Pharmaceutical formulations of a hif hydroxylase inhibitor

Publications (3)

Publication Number Publication Date
IL242759A true IL242759A (cg-RX-API-DMAC10.html) 2015-12-31
IL242759B1 IL242759B1 (en) 2023-01-01
IL242759B2 IL242759B2 (en) 2023-05-01

Family

ID=51063834

Family Applications (3)

Application Number Title Priority Date Filing Date
IL296484A IL296484B2 (en) 2013-06-06 2014-06-05 Pharmaceutical formulations of HIF hydroxylase inhibitor
IL298998A IL298998B2 (en) 2013-06-06 2014-06-05 Pharmaceutical formulations of a hif hydroxylase inhibitor
IL242759A IL242759B2 (en) 2013-06-06 2015-11-24 Pharmaceutical formulations of hif hydroxylase inhibitor

Family Applications Before (2)

Application Number Title Priority Date Filing Date
IL296484A IL296484B2 (en) 2013-06-06 2014-06-05 Pharmaceutical formulations of HIF hydroxylase inhibitor
IL298998A IL298998B2 (en) 2013-06-06 2014-06-05 Pharmaceutical formulations of a hif hydroxylase inhibitor

Country Status (24)

Country Link
US (3) US20160120859A1 (cg-RX-API-DMAC10.html)
EP (2) EP3003284B1 (cg-RX-API-DMAC10.html)
JP (4) JP6604941B2 (cg-RX-API-DMAC10.html)
KR (3) KR102291860B1 (cg-RX-API-DMAC10.html)
CN (5) CN105377242A (cg-RX-API-DMAC10.html)
AU (1) AU2014274890B2 (cg-RX-API-DMAC10.html)
CA (1) CA2914049C (cg-RX-API-DMAC10.html)
CY (1) CY1122951T1 (cg-RX-API-DMAC10.html)
DK (1) DK3003284T3 (cg-RX-API-DMAC10.html)
ES (1) ES2786924T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20200615T1 (cg-RX-API-DMAC10.html)
HU (1) HUE049623T2 (cg-RX-API-DMAC10.html)
IL (3) IL296484B2 (cg-RX-API-DMAC10.html)
LT (1) LT3003284T (cg-RX-API-DMAC10.html)
ME (1) ME03777B (cg-RX-API-DMAC10.html)
MX (3) MX2015016536A (cg-RX-API-DMAC10.html)
PL (1) PL3003284T3 (cg-RX-API-DMAC10.html)
PT (1) PT3003284T (cg-RX-API-DMAC10.html)
RS (1) RS60464B1 (cg-RX-API-DMAC10.html)
SG (1) SG11201509764RA (cg-RX-API-DMAC10.html)
SI (1) SI3003284T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202000190T1 (cg-RX-API-DMAC10.html)
WO (1) WO2014197660A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201508712B (cg-RX-API-DMAC10.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103145616B (zh) 2003-06-06 2015-09-30 菲布罗根有限公司 含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途
WO2010056767A1 (en) 2008-11-14 2010-05-20 Fibrogen, Inc. Thiochromene derivatives as hip hydroxylase inhibitors
SG11201500234YA (en) 2012-07-16 2015-02-27 Fibrogen Inc Process for making isoquinoline compounds
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
EP3470397B1 (en) 2012-07-16 2021-12-29 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
IL296484B2 (en) 2013-06-06 2025-03-01 Fibrogen Inc Pharmaceutical formulations of HIF hydroxylase inhibitor
NZ735973A (en) 2015-04-01 2023-06-30 Akebia Therapeutics Inc Compositions and methods for treating anemia
WO2019042485A1 (en) 2017-08-30 2019-03-07 Zentiva, K.S. FORMS IN THE STRONG STATE OF ROXADUSTAT
ES2898878T3 (es) 2017-09-04 2022-03-09 Sandoz Ag Cocristal de un inhibidor de la prolil·hidroxilasa de HIF disponible por vía oral
CN110664814A (zh) * 2019-10-24 2020-01-10 上海长海医院 Fg-4592在制备治疗炎性肠病药物中的用途
CN110934833B (zh) * 2019-12-17 2022-08-19 河北长天药业有限公司 一种复方氨酚那敏颗粒
EP4121009A4 (en) * 2020-03-17 2024-04-17 Zydus Lifesciences Limited Formulation comprising hif prolyl hydroxylase inhibitors
WO2021216530A1 (en) 2020-04-20 2021-10-28 Akebia Therapeutics, Inc. Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer
WO2022192097A1 (en) * 2021-03-06 2022-09-15 Mind Medicine, Inc. Formulations of psilocin that have enhanced stability
WO2023140901A1 (en) * 2022-01-21 2023-07-27 Elanco Us Inc. Molidustat formulations and methods of use for treatment of anemia in cats
CN116832005A (zh) * 2022-03-23 2023-10-03 石药集团中奇制药技术（石家庄）有限公司 一种罗沙司他胶囊
CN114796280B (zh) * 2022-06-15 2024-06-25 河北长天药业有限公司 一种复方氨酚那敏颗粒及其制备工艺
EP4321155A1 (en) * 2022-08-08 2024-02-14 Sanovel Ilac Sanayi Ve Ticaret A.S. An oral pharmaceutical composition comprising roxadustat
WO2025111214A1 (en) 2023-11-22 2025-05-30 Fibrogen, Inc. [(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3- carbonyl)amino]acetic acid (roxadustat) for the treatment of anemia in subjects with myelodysplastic syndrome (mds)
CN118436652A (zh) * 2024-04-18 2024-08-06 南方医科大学顺德医院(佛山市顺德区第一人民医院) 一种罗沙司他药物制剂及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090099203A1 (en) * 2007-10-12 2009-04-16 Astrazeneca Ab Composition 064
US20100172984A1 (en) * 2006-06-06 2010-07-08 Bijay Kumar Padhi tablet dosage form comprising cetirizine and pseudoephedrine
US20120149712A1 (en) * 2001-12-06 2012-06-14 Fibrogen, Inc. Methods for improving kidney function
WO2012097331A1 (en) * 2011-01-13 2012-07-19 Fibrogen, Inc. Methods for increasing reticulocyte hemoglobin content

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0650961B1 (de) 1993-11-02 1997-03-05 Hoechst Aktiengesellschaft Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
HU229475B1 (en) 2001-12-06 2014-01-28 Fibrogen Methods of increasing endogenous erythropoietin (epo)
DE10209692A1 (de) 2002-03-06 2003-09-18 Merck Patent Gmbh Isochinolinderivate
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
JP4805234B2 (ja) * 2002-12-16 2011-11-02 キッセイ薬品工業株式会社 経口固形医薬
US20060018959A1 (en) 2002-12-16 2006-01-26 Kissei Pharmaceutical Co. Ltd. Solid drug for oral use
CN103145616B (zh) 2003-06-06 2015-09-30 菲布罗根有限公司 含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
EP1658074B1 (en) 2003-08-01 2012-11-07 Fibrogen, Inc. Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers
WO2005087237A1 (ja) * 2004-03-16 2005-09-22 Asahi Kasei Pharma Corporation ファスジル含有製剤及びその安定性を改善する方法
US8703795B2 (en) 2005-03-02 2014-04-22 Fibrogen, Inc. Thienopyridine compounds, and methods of use thereof
CN101849943A (zh) 2005-06-06 2010-10-06 菲布罗根公司 使用HIFα稳定剂的改进的贫血治疗
AU2006259352A1 (en) 2005-06-15 2006-12-28 Fibrogen, Inc. Use of HIF 1alfa modulators for treatment of cancer
UA97349C2 (uk) 2005-09-08 2012-02-10 Х. Луннбэк А/С Стійкі тверді склади сертиндолу
EP1944029B1 (en) 2005-10-31 2011-12-21 Kowa Company, Ltd. Pharmaceutical preparation having excellent photostability
GB0523810D0 (en) 2005-11-23 2006-01-04 Astrazeneca Ab Pharmaceutical compositions
CN102351791B (zh) 2006-01-27 2014-10-29 菲布罗根有限公司 使低氧诱导因子(hif)稳定的氰基异喹啉化合物
JP2009526047A (ja) * 2006-02-09 2009-07-16 テバ ファーマシューティカル インダストリーズ リミティド モンテルカストナトリウムの安定な医薬製剤
US20070259960A1 (en) 2006-02-16 2007-11-08 Fibrogen, Inc. Compounds and methods for treatment of stroke
AU2007234408B2 (en) 2006-04-04 2011-05-19 Fibrogen, Inc. Pyrrolo- and thiazolo-pyridine compounds as HIF modulators
US20070293575A1 (en) 2006-06-15 2007-12-20 Fibrogen, Inc. Compounds and methods for treatment of cancer-related anemia
US7713986B2 (en) 2006-06-15 2010-05-11 Fibrogen, Inc. Compounds and methods for treatment of chemotherapy-induced anemia
JP5683058B2 (ja) 2007-04-27 2015-03-11 ニプロ株式会社 経口固形製剤及びその製造方法
WO2009058403A1 (en) 2007-11-02 2009-05-07 Fibrogen, Inc. Methods for reducing blood pressure
WO2009073669A1 (en) 2007-12-03 2009-06-11 Fibrogen, Inc. Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions
US20110039885A1 (en) 2007-12-06 2011-02-17 Fibrogen, Inc. Methods for increasing endothelial progenitor cells
EP2231156A1 (en) 2007-12-07 2010-09-29 Fibrogen, Inc. Methods for increasing white blood cells
US8952160B2 (en) 2008-01-11 2015-02-10 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity
US8324405B2 (en) 2008-02-05 2012-12-04 Fibrogen, Inc. Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors
CN102264740B (zh) 2008-08-20 2014-10-15 菲布罗根有限公司 一种吡咯[1,2-b]哒嗪衍生物及其作为hif调节剂的用途
WO2010024908A1 (en) 2008-08-26 2010-03-04 Fibrogen, Inc. Methods for treatment of multiple sclerosis
WO2010056767A1 (en) 2008-11-14 2010-05-20 Fibrogen, Inc. Thiochromene derivatives as hip hydroxylase inhibitors
US20100144737A1 (en) 2008-12-08 2010-06-10 Fibrogen, Inc. Methods for inhibiting t helper cell differentiation
WO2010087462A1 (ja) 2009-01-29 2010-08-05 大日本住友製薬株式会社 内核を有する口腔内崩壊錠
JP2010248106A (ja) * 2009-04-14 2010-11-04 Dainippon Sumitomo Pharma Co Ltd フィルムコーティング錠
JP2012176899A (ja) * 2009-05-19 2012-09-13 Mitsubishi Tanabe Pharma Corp ２−（１−ピペラジニル）−５−メチルベンゼンスルホン酸誘導体を含む注射用水溶液
WO2012097329A1 (en) 2011-01-13 2012-07-19 Fibrogen, Inc. Methods for increasing mean corpuscular volume
EP2670750B1 (en) 2011-02-02 2016-09-14 Fibrogen, Inc. Naphthyridine derivatives as inhibitors of hypoxia inducible factor
CA2842730C (en) 2011-07-22 2018-08-21 Beijing Betta Pharmaceuticals Co., Ltd Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof
US20140309256A1 (en) 2011-11-09 2014-10-16 Fibrogen, Inc. Therapeutic Method
WO2013134660A1 (en) 2012-03-09 2013-09-12 Fibrogen, Inc. 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors
EP3470397B1 (en) 2012-07-16 2021-12-29 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
SG11201500234YA (en) 2012-07-16 2015-02-27 Fibrogen Inc Process for making isoquinoline compounds
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
SG10202009266PA (en) 2013-01-24 2020-10-29 Fibrogen Inc Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid
IL296484B2 (en) 2013-06-06 2025-03-01 Fibrogen Inc Pharmaceutical formulations of HIF hydroxylase inhibitor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120149712A1 (en) * 2001-12-06 2012-06-14 Fibrogen, Inc. Methods for improving kidney function
US20100172984A1 (en) * 2006-06-06 2010-07-08 Bijay Kumar Padhi tablet dosage form comprising cetirizine and pseudoephedrine
US20090099203A1 (en) * 2007-10-12 2009-04-16 Astrazeneca Ab Composition 064
WO2012097331A1 (en) * 2011-01-13 2012-07-19 Fibrogen, Inc. Methods for increasing reticulocyte hemoglobin content

Also Published As

Publication number Publication date
RU2015151056A3 (cg-RX-API-DMAC10.html) 2018-05-03
RS60464B1 (sr) 2020-07-31
AU2014274890B2 (en) 2019-10-03
LT3003284T (lt) 2020-04-27
IL242759B1 (en) 2023-01-01
IL296484B1 (en) 2024-11-01
CY1122951T1 (el) 2021-10-29
US10765672B2 (en) 2020-09-08
IL242759B2 (en) 2023-05-01
JP2023068197A (ja) 2023-05-16
RU2681304C2 (ru) 2019-03-06
ME03777B (me) 2021-04-20
IL296484B2 (en) 2025-03-01
JP6604941B2 (ja) 2019-11-13
US20190008846A1 (en) 2019-01-10
SMT202000190T1 (it) 2020-05-08
PT3003284T (pt) 2020-08-10
JP6861758B2 (ja) 2021-04-21
ZA201508712B (en) 2020-07-29
ES2786924T3 (es) 2020-10-14
HUE049623T2 (hu) 2020-09-28
BR112015029693A2 (pt) 2017-07-25
RU2015151056A (ru) 2017-07-14
CN111728950A (zh) 2020-10-02
CN111728952A (zh) 2020-10-02
MX2020003096A (es) 2020-08-17
DK3003284T3 (da) 2020-03-30
IL296484A (en) 2022-11-01
BR112015029693A8 (pt) 2019-12-24
KR102291860B1 (ko) 2021-08-20
WO2014197660A1 (en) 2014-12-11
JP2019137703A (ja) 2019-08-22
SG11201509764RA (en) 2015-12-30
KR20160018514A (ko) 2016-02-17
KR20210104173A (ko) 2021-08-24
CA2914049A1 (en) 2014-12-11
SI3003284T1 (sl) 2020-08-31
AU2014274890A1 (en) 2015-12-17
CN111728951A (zh) 2020-10-02
IL298998A (en) 2023-02-01
US20160120859A1 (en) 2016-05-05
EP3708154A1 (en) 2020-09-16
IL298998B2 (en) 2024-07-01
JP2021100971A (ja) 2021-07-08
JP2016523846A (ja) 2016-08-12
NZ714554A (en) 2021-06-25
US20220054474A1 (en) 2022-02-24
HK1222550A1 (en) 2017-07-07
HRP20200615T1 (hr) 2020-07-10
MX2015016536A (es) 2016-08-11
PL3003284T3 (pl) 2020-08-10
EP3003284A1 (en) 2016-04-13
CN110448537A (zh) 2019-11-15
IL298998B1 (en) 2024-03-01
NZ754196A (en) 2021-06-25
CN105377242A (zh) 2016-03-02
EP3003284B1 (en) 2020-02-12
CA2914049C (en) 2021-10-12
MX2022011225A (es) 2022-10-07
KR20220164069A (ko) 2022-12-12

Similar Documents

Publication Publication Date Title
AP2016009275A0 (cg-RX-API-DMAC10.html)
BR112016011257A2 (cg-RX-API-DMAC10.html)
BR112015007533A2 (cg-RX-API-DMAC10.html)
BR102016010778A2 (cg-RX-API-DMAC10.html)
BR112014017733A2 (cg-RX-API-DMAC10.html)
BR112014017739A2 (cg-RX-API-DMAC10.html)
BR112014018502A2 (cg-RX-API-DMAC10.html)
BR112014018516A2 (cg-RX-API-DMAC10.html)
BR112014017765A2 (cg-RX-API-DMAC10.html)
BR112014018480A2 (cg-RX-API-DMAC10.html)
BR112014017855A2 (cg-RX-API-DMAC10.html)
BR112014020341A2 (cg-RX-API-DMAC10.html)
BR112014017669A2 (cg-RX-API-DMAC10.html)
BR112014018468A2 (cg-RX-API-DMAC10.html)
BR112014017901A2 (cg-RX-API-DMAC10.html)
BR112016009041A2 (cg-RX-API-DMAC10.html)
BR112014017722A2 (cg-RX-API-DMAC10.html)
BR112014017653A2 (cg-RX-API-DMAC10.html)
BR112016011185A2 (cg-RX-API-DMAC10.html)
BR112014018578A2 (cg-RX-API-DMAC10.html)
BR112016004058A2 (cg-RX-API-DMAC10.html)
BR112014017601A2 (cg-RX-API-DMAC10.html)
BR112015015312A2 (cg-RX-API-DMAC10.html)
BR112014024039A2 (cg-RX-API-DMAC10.html)
BR112014018353A2 (cg-RX-API-DMAC10.html)